Efficacy and Safety of CSA and Avatrombopag for the Treatment of SAA in the Elderly
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, single-arm clinical study. The objective was to evaluate the efficacy
and safety of CSA in combination with Avatrombopag in elderly patients with very/sever
aplastic anemia treated for the first time. The design was: cyclosporine 3 mg/kg orally in
two divided doses, with cyclosporine trough concentrations maintained at 200-250 ng/ml for 3
months to achieve maximum efficacy, and Avatrombopag, which was administered in two dose
groups, 40 mg orally once daily and 60 mg orally once daily, for a total of 24 weeks. Forty
patients are expected to be enrolled in each dose group, and a total of 80 patients are
expected to be enrolled if both dose groups are conducted. Evaluation endpoint: OR rate at 24
weeks of treatment.